Fig. 2From: Efficacy and safety of erenumab in Japanese migraine patients with prior preventive treatment failure or concomitant preventive treatment: subgroup analyses of a phase 3, randomized trial≥50% reduction in mean MMD from baseline in (A) failed-yes/no and (B) concomitant preventive-yes/no subgroups. CI confidence interval, MMD monthly migraine days, OR odds ratioBack to article page